Skip to main content

Table 4 Major adverse cardiac events, mortality and bleeding events at 30 days in the protocol (n = 99) and non-protocol (n = 291) treated groups

From: Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction

  Protocol Non-protocol p-value
n (%) n (%)
MACE 6 (6.1) 31 (10.7) 0.178
 Cardiovascular death 4 (4.0) 26 (8.9) 0.114
 Non-fatal myocardial infarction 0 (0) 1 (0.3) 0.559
 Non-fatal stroke 1 (1.0) 4 (1.4) 0.781
 Target vessel revascularisation 1 (1.0) 3 (1.0) 0.986
Death from any cause 5 (5.1) 28 (9.6) 0.158
Severe GUSTO bleeding 0 (0) 3 (1.0) 0.311
 Mild or minor GUSTO bleeding 3 (3.0) 6 (2.1) 0.579
Major TIMI bleeding 0 (0) 1 (0.3) 0.559
 Minor or minimal TIMI bleeding 2 (2.0) 4 (1.4) 0.652